...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand.
【24h】

Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand.

机译:小鼠皮肤同种异体移植在接受供体脾细胞和CD40配体抗体治疗的受体中存活时间延长。

获取原文
获取原文并翻译 | 示例

摘要

Combined treatment with antibody against CD40 ligand and one transfusion of donor splenocytes prolonged survival of fully mismatched BALB/c skin allografts on C57BL/6 recipients, with approximately 20% of grafts surviving > 100 days. In vitro alloresponsiveness in treated animals was reduced in the immediate post-transplantation period, but by day 100 was increased despite the presence of a successful allograft. The presence of alloreactivity on day 100 was confirmed in vivo by adoptive transfer, which suggests that our protocol had induced either a state of "split tolerance" or "graft accommodation." Mice with skin grafts that had survived for > or = 100 days revealed no evidence of lymphoid chimerism. Treatment with donor splenocytes and antibody against CD40 ligand permits long-term survival of highly antigenic donor skin allografts despite the presence of functionally intact alloreactive lymphocytes.
机译:结合抗CD40配体的抗体和一次输注供体脾细胞的联合治疗,可以延长完全错配的BALB / c皮肤同种异体移植物在C57BL / 6受体上的存活,其中约20%的移植物存活时间超过100天。在移植后即刻,治疗动物的体外同种异体反应性降低,但是尽管存在成功的同种异体移植,但到第100天仍增加。通过过继转移体内证实了在第100天存在同种反应性,这表明我们的方案已经诱导了“分裂耐受”或“移植适应”状态。存活时间大于或等于100天的皮肤移植小鼠没有淋巴嵌合体的迹象。尽管存在功能完整的同种异体反应性淋巴细胞,但使用供体脾细胞和抗CD40配体的抗体进行治疗仍可以长期保留高度抗原性供体皮肤同种异体移植物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号